TuHURA Biosciences Inc (HURA)

Form 8-K - Current report

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update

TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update PR Newswire...

TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference PR Newswire...

Form 8-K/A - Current report: [Amend]

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]

Form 8-K - Current report

TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028

TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations

TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations PR...

Form 8-K - Current report

TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate...